Arvinas and Rigel Reach Licensing Agreement for Breast Cancer Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PFE?
Source: seekingalpha
- Agreement Reached: Arvinas (ARVN) and Pfizer (PFE) have finalized an agreement to sell global licensing rights for their jointly developed breast cancer therapy, Veppanu, to Rigel (RIGL), marking a significant advancement in breast cancer treatment.
- Cash Inflow: Rigel (RIGL) will provide $70 million upfront to Arvinas (ARVN) and Pfizer (PFE), along with an additional $15 million contingent on specific development and manufacturing milestones, significantly enhancing the funding capabilities for ongoing R&D activities.
- Milestone Payments: The agreement includes up to $320 million in milestone payments and tiered royalties on net sales ranging from the mid-teens to mid-20s, indicating substantial market potential for the therapy and promising long-term revenue for the partners.
- Global Market Expansion: Rigel (RIGL) will receive global rights to Veppanu, including sublicensing rights in overseas territories, which not only broadens market reach but also provides Arvinas (ARVN) and Pfizer (PFE) with additional revenue streams, further solidifying their positions in the global biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.870
Low
24.00
Averages
28.56
High
35.00
Current: 25.870
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alibaba Reports Weak Earnings Growth Amid AI Spending
- Alibaba Earnings Report: Alibaba's fiscal fourth-quarter results revealed a mere 3% revenue growth, while on a like-for-like basis, excluding disposed businesses, it would have shown an 11% year-over-year increase; however, profitability sharply declined due to increased AI-related spending, compressing adjusted EBITA and net income, indicating significant pressure on earnings in a rapidly evolving market.
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year revenue increase to $399 million for the quarter ending March 31, driven by soaring artificial intelligence expenditures, although it posted an adjusted net loss of $100.3 million, its GAAP earnings per share of $2.82 reflect strong market demand and growth potential.
- Two Harbors Rejects Acquisition: Two Harbors Investment's board unanimously rejected UWM Holdings' revised acquisition proposal, citing unresolved “core deficiencies and material risks” from previous proposals, leading to a 2.1% decline in its stock price during premarket trading, showcasing the company's cautious stance on acquisitions.
- Pfizer Drug Approval: Pfizer announced that its hemophilia therapy Hympavzi received marketing authorization from the European Commission to expand its label for use in adolescents, now indicated in all 27 EU member states as well as Iceland, Liechtenstein, and Norway for hemophilia A or B patients aged 12 and older, despite a 0.50% drop in premarket trading, this approval could open new market opportunities for the company.
See More
Pfizer Expands Hympavzi Indication to Adolescents
- Market Authorization Expansion: Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the indication of its hemophilia therapy, Hympavzi, to adolescents aged 12 and older, covering all 27 EU member states as well as Iceland, Liechtenstein, and Norway, significantly enhancing the drug's market potential.
- Patient Need Addressed: Approximately 20% of hemophilia A patients and 3% of hemophilia B patients are unable to continue factor replacement therapies due to the development of inhibitory antibodies, and the approval of Hympavzi will provide new treatment options for these patients, improving their quality of life.
- FDA Priority Review: Earlier this year, Pfizer received priority review from the FDA for its marketing application aimed at expanding the Hympavzi label in the U.S. for hemophilia A or B patients aged six and older, with a final decision expected in Q2 2026, further strengthening Pfizer's competitive position in the hemophilia treatment space.
- Strategic Implications: This indication expansion not only enhances Pfizer's standing in the hemophilia market but may also drive future revenue growth for the company, particularly in the context of increasing patient demand and market competition.
See More
FDA Commissioner Marty Makary Ousted Amid Controversies
- Leadership Change at FDA: Marty Makary's departure on Tuesday, with Deputy Commissioner Kyle Diamantas stepping in as acting commissioner, reflects growing dissatisfaction within the Trump administration regarding the FDA's chaotic management, potentially impacting the agency's policy direction and industry trust.
- Industry Reactions: Under Makary's tenure, the FDA faced significant controversies, particularly with Replimune criticizing the agency for rejecting its melanoma treatment, which led to an over 8% rise in its stock on Tuesday, indicating market sensitivity to FDA decisions.
- Regulatory Decision Controversies: Makary's term has been marred by accusations of conflicts of interest in FDA regulatory decisions, and the use of “expert panels” often contradicting mainstream medical opinions, which may undermine public trust in the agency.
- Impact on Other Companies: Companies like Regenxbio and Moderna also faced FDA rejections during Makary's leadership, affecting their product approval timelines and potentially leading to negative implications for future R&D investment decisions.
See More
Pfizer's Growth Potential Through New Products and Pipeline Progress
- New Product Sales Growth: Pfizer's respiratory syncytial virus vaccine, Abrysvo, generated $180 million in sales in Q1, reflecting a 37% year-over-year increase, indicating the potential of new products to drive revenue despite challenges from traditional drugs like Eliquis facing patent expirations.
- Financial Performance Volatility: Pfizer's revenue grew 5% year-over-year to $14.5 billion in Q1; however, financial results may worsen due to patent cliffs, with the market seemingly pricing this in, suggesting that stock prices could rebound as new products gain traction.
- Pipeline Outlook: Pfizer is set to initiate around 20 pivotal studies by 2026, with promising candidates like Ecnoglutide for obesity management recently approved in China, indicating potential new revenue streams in the anti-obesity market.
- Long-Term Investment Opportunity: As Pfizer's pipeline progresses, particularly with drugs entering clinical phases, the stock is expected to perform well through 2031 and beyond, making it a compelling option for long-term investors looking to capitalize on future growth.
See More
Rigel Partners with Arvinas and Pfizer for Breast Cancer Treatment
- FDA Approval: Vepdegestrant, branded as Veppanu, received FDA approval earlier this month, becoming the only FDA-approved oral PROTAC therapy, which is expected to drive Rigel's cancer treatment portfolio expansion and enhance market competitiveness.
- Financial Gains from Agreement: Rigel will receive $70 million upfront and an additional $15 million upon completion of transition activities, along with potential future milestone payments of up to $320 million, significantly improving the company's financial outlook and investor confidence.
- Positive Stock Reaction: Rigel's shares surged over 15% following the announcement of the agreement, reflecting investor optimism regarding the new drug's market potential and indicating the company's growth prospects in oncology.
- Clinical Data Support: Veppanu demonstrated a 43% reduction in disease progression risk in Phase 3 studies, with a median progression-free survival of five months compared to 2.1 months for the comparator drug Fulvestrant, highlighting its significant therapeutic advantage.
See More
Arvinas and Rigel Reach Licensing Agreement for Breast Cancer Therapy
- Agreement Reached: Arvinas (ARVN) and Pfizer (PFE) have finalized an agreement to sell global licensing rights for their jointly developed breast cancer therapy, Veppanu, to Rigel (RIGL), marking a significant advancement in breast cancer treatment.
- Cash Inflow: Rigel (RIGL) will provide $70 million upfront to Arvinas (ARVN) and Pfizer (PFE), along with an additional $15 million contingent on specific development and manufacturing milestones, significantly enhancing the funding capabilities for ongoing R&D activities.
- Milestone Payments: The agreement includes up to $320 million in milestone payments and tiered royalties on net sales ranging from the mid-teens to mid-20s, indicating substantial market potential for the therapy and promising long-term revenue for the partners.
- Global Market Expansion: Rigel (RIGL) will receive global rights to Veppanu, including sublicensing rights in overseas territories, which not only broadens market reach but also provides Arvinas (ARVN) and Pfizer (PFE) with additional revenue streams, further solidifying their positions in the global biopharmaceutical market.
See More
Alibaba Reports Weak Earnings Growth Amid AI Spending
- Alibaba Earnings Report: Alibaba's fiscal fourth-quarter results revealed a mere 3% revenue growth, while on a like-for-like basis, excluding disposed businesses, it would have shown an 11% year-over-year increase; however, profitability sharply declined due to increased AI-related spending, compressing adjusted EBITA and net income, indicating significant pressure on earnings in a rapidly evolving market.
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year revenue increase to $399 million for the quarter ending March 31, driven by soaring artificial intelligence expenditures, although it posted an adjusted net loss of $100.3 million, its GAAP earnings per share of $2.82 reflect strong market demand and growth potential.
- Two Harbors Rejects Acquisition: Two Harbors Investment's board unanimously rejected UWM Holdings' revised acquisition proposal, citing unresolved “core deficiencies and material risks” from previous proposals, leading to a 2.1% decline in its stock price during premarket trading, showcasing the company's cautious stance on acquisitions.
- Pfizer Drug Approval: Pfizer announced that its hemophilia therapy Hympavzi received marketing authorization from the European Commission to expand its label for use in adolescents, now indicated in all 27 EU member states as well as Iceland, Liechtenstein, and Norway for hemophilia A or B patients aged 12 and older, despite a 0.50% drop in premarket trading, this approval could open new market opportunities for the company.
See More
Pfizer Expands Hympavzi Indication to Adolescents
- Market Authorization Expansion: Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the indication of its hemophilia therapy, Hympavzi, to adolescents aged 12 and older, covering all 27 EU member states as well as Iceland, Liechtenstein, and Norway, significantly enhancing the drug's market potential.
- Patient Need Addressed: Approximately 20% of hemophilia A patients and 3% of hemophilia B patients are unable to continue factor replacement therapies due to the development of inhibitory antibodies, and the approval of Hympavzi will provide new treatment options for these patients, improving their quality of life.
- FDA Priority Review: Earlier this year, Pfizer received priority review from the FDA for its marketing application aimed at expanding the Hympavzi label in the U.S. for hemophilia A or B patients aged six and older, with a final decision expected in Q2 2026, further strengthening Pfizer's competitive position in the hemophilia treatment space.
- Strategic Implications: This indication expansion not only enhances Pfizer's standing in the hemophilia market but may also drive future revenue growth for the company, particularly in the context of increasing patient demand and market competition.
See More
FDA Commissioner Marty Makary Ousted Amid Controversies
- Leadership Change at FDA: Marty Makary's departure on Tuesday, with Deputy Commissioner Kyle Diamantas stepping in as acting commissioner, reflects growing dissatisfaction within the Trump administration regarding the FDA's chaotic management, potentially impacting the agency's policy direction and industry trust.
- Industry Reactions: Under Makary's tenure, the FDA faced significant controversies, particularly with Replimune criticizing the agency for rejecting its melanoma treatment, which led to an over 8% rise in its stock on Tuesday, indicating market sensitivity to FDA decisions.
- Regulatory Decision Controversies: Makary's term has been marred by accusations of conflicts of interest in FDA regulatory decisions, and the use of “expert panels” often contradicting mainstream medical opinions, which may undermine public trust in the agency.
- Impact on Other Companies: Companies like Regenxbio and Moderna also faced FDA rejections during Makary's leadership, affecting their product approval timelines and potentially leading to negative implications for future R&D investment decisions.
See More
Pfizer's Growth Potential Through New Products and Pipeline Progress
- New Product Sales Growth: Pfizer's respiratory syncytial virus vaccine, Abrysvo, generated $180 million in sales in Q1, reflecting a 37% year-over-year increase, indicating the potential of new products to drive revenue despite challenges from traditional drugs like Eliquis facing patent expirations.
- Financial Performance Volatility: Pfizer's revenue grew 5% year-over-year to $14.5 billion in Q1; however, financial results may worsen due to patent cliffs, with the market seemingly pricing this in, suggesting that stock prices could rebound as new products gain traction.
- Pipeline Outlook: Pfizer is set to initiate around 20 pivotal studies by 2026, with promising candidates like Ecnoglutide for obesity management recently approved in China, indicating potential new revenue streams in the anti-obesity market.
- Long-Term Investment Opportunity: As Pfizer's pipeline progresses, particularly with drugs entering clinical phases, the stock is expected to perform well through 2031 and beyond, making it a compelling option for long-term investors looking to capitalize on future growth.
See More
Rigel Partners with Arvinas and Pfizer for Breast Cancer Treatment
- FDA Approval: Vepdegestrant, branded as Veppanu, received FDA approval earlier this month, becoming the only FDA-approved oral PROTAC therapy, which is expected to drive Rigel's cancer treatment portfolio expansion and enhance market competitiveness.
- Financial Gains from Agreement: Rigel will receive $70 million upfront and an additional $15 million upon completion of transition activities, along with potential future milestone payments of up to $320 million, significantly improving the company's financial outlook and investor confidence.
- Positive Stock Reaction: Rigel's shares surged over 15% following the announcement of the agreement, reflecting investor optimism regarding the new drug's market potential and indicating the company's growth prospects in oncology.
- Clinical Data Support: Veppanu demonstrated a 43% reduction in disease progression risk in Phase 3 studies, with a median progression-free survival of five months compared to 2.1 months for the comparator drug Fulvestrant, highlighting its significant therapeutic advantage.
See More
Arvinas and Rigel Reach Licensing Agreement for Breast Cancer Therapy
- Agreement Reached: Arvinas (ARVN) and Pfizer (PFE) have finalized an agreement to sell global licensing rights for their jointly developed breast cancer therapy, Veppanu, to Rigel (RIGL), marking a significant advancement in breast cancer treatment.
- Cash Inflow: Rigel (RIGL) will provide $70 million upfront to Arvinas (ARVN) and Pfizer (PFE), along with an additional $15 million contingent on specific development and manufacturing milestones, significantly enhancing the funding capabilities for ongoing R&D activities.
- Milestone Payments: The agreement includes up to $320 million in milestone payments and tiered royalties on net sales ranging from the mid-teens to mid-20s, indicating substantial market potential for the therapy and promising long-term revenue for the partners.
- Global Market Expansion: Rigel (RIGL) will receive global rights to Veppanu, including sublicensing rights in overseas territories, which not only broadens market reach but also provides Arvinas (ARVN) and Pfizer (PFE) with additional revenue streams, further solidifying their positions in the global biopharmaceutical market.
See More
